Bioline Rx reported $2.5M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Arca Biopharma USD 268.47M 218.95M Jun/2026
Bio Path 13.65M 3.37M Sep/2022
Bioline Rx USD 2.5M 5.41M Mar/2026
Capricor Therapeutics USD 20.94M 84.49M Jun/2026